relat debt extinguish includ
one-tim non-cash charg relat debt
updat guidanc
sale outpac our/street
estim underli momentum custom stock given
recurring-busi model higher sale guidanc constant
currenc maintain though expect low end expect
signific impact new patient start gradual recoveri throughout
lower expect new patient start impact sale given
better underli perform still target sale next year rapidli
expect horizon launch us pharmaci channel expans
new us omnipod user remain tailwind
impact manag expect recessionari headwind persist
throughout gradual recoveri start market dynam
normal endocrinologist visit sinc march versu prior
expect expect quarterli reduct new patient start
anticip downward pressur
util uptick attrit
margin outlook management expect gm approxim due
anticip reduct volum slower us manufactur ramp gm
also impact addit one-tim cost relat
guidanc mid-teen closer low end
note us/ou omnipod sale saw roughli custom
stock due almost us custom go
pharmaci us new omniopod start addit medicare/
medicaid coverag omnipod us reach respect
dash cover commerci insur live
note complet horizon softwar updat resubmit
back fda review expect restart trial june us launch
drug deliveri sale declin due shift product time
management note onboard new user recent week via virtual train
clinic trainer mdi user
estim impact lower sale estim
y/i ep estim goe lower
sales/expect gm forecast sale ep
underli momentum channel initi peer multipl expans
partial off-set impact pt rise
year price histori
market insulin infus system
peopl
diabet primari product
analyst certif import disclosur see disclosur
growth us market
long-term gross margin
omnipod tubeless insulin pump uniqu offer
diabet pump space compani sever
opportun ahead includ entranc medicare/
medicaid popul dash next gener platform
provid entri pharmaci channel horizon
autom glucos control system combin
cgm target launch rate perform
omnipod dash roll-out europ canada well ou
horizon target launch
greater expect gross margin expans quicker sale
expans new countri
greater impact new patient start forecast
slowdown market share gain competitor hybrid close loop
launch ahead horizon
price target driven discount cash flow analysi ev/sal multipl analysi dcf assum
weight averag cost capit wacc termin growth rate estim ebitda pt
impli sale estim line peer
sale market
gener administr
footnot includ one-tim non-cash charg relat debt extinguish
footnot includ one-tim non-cash charg relat debt extinguish
